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Objectives The purpose of this study was to investigate the impact of renin-angiotensin system blockade therapy on out-
comes in aortic stenosis (AS).
Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are perceived to be
relatively contraindicated in AS. However, inhibitors of the renin-angiotensin system may be beneficial in AS
through their cardioprotective and beneficial effects on left ventricular remodeling.
Methods The Health Informatics dispensed prescribing, morbidity, and mortality database for the population of Tayside,
Scotland, was linked through a unique patient identifier to the Tayside echocardiography database (110,000
scans). Patients with a diagnosis of AS from 1993 to 2008 were identified. Cox regression model (adjusted for
confounding variables) and propensity score analysis were used to assess the impact of ACEIs or ARBs on all-
cause mortality and cardiovascular (CV) events (CV death or hospitalizations).
Results A total of 2,117 patients with AS (mean age 73  12 years, 46% men) were identified and 699 (33%) were on
ACEI or ARB therapy. Over a mean follow-up of 4.2 years, there were 1,087 (51%) all-cause deaths and 1,018
(48%) CV events. Those treated with ACEIs or ARBs had a significantly lower all-cause mortality with an adjusted
hazard ratio of 0.76 (95% confidence interval: 0.62 to 0.92, p  0.0001) and fewer CV events with an adjusted
hazard ratio of 0.77 (95% confidence interval: 0.65 to 0.92, p  0.0001). The outcome benefits of ACEIs/ARBs
were further supported by propensity score analysis.
Conclusions This large observational study suggests that ACEI/ARB therapy is associated with an improved survival and a
lower risk of CV events in patients with AS. (J Am Coll Cardiol 2011;58:570–6) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.063Aortic stenosis (AS) is a common valvular disease, affecting
2% to 4% of adults older than age 65 years (1). It is a
progressive disease with a long asymptomatic phase, but
once symptoms develop, the prognosis is poor (2). Current
treatment strategies include careful monitoring and judi-
cious timing of aortic valve replacement (AVR). Unfortu-
nately, not everyone is suitable for surgery, and alternative
techniques like transcatheter aortic valve implantation have
limited availability, creating a need for medical therapy.
The renin-angiotensin system (RAS) is activated at an
early stage in AS, promoting development of left ventricular
hypertrophy (LVH), myocardial fibrosis, myocardial con-
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2011, accepted January 17, 2011.tractile failure, and diastolic dysfunction (3). In animal
models of AS, angiotensin-converting enzyme inhibitor
(ACEI) therapy has been shown to regress LVH, improve
myocardial contractility, and delay progression to heart
failure (4,5). Clinical data have now shown that both
ACEIs and angiotensin receptor blockers (ARBs) have
beneficial effects on LVH, adverse left ventricular (LV)
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remodeling, LV dysfunction, and atherosclerosis and im-
prove the prognosis in these conditions (6,7). Given the
pivotal pathophysiological role of the RAS in adverse LV
remodeling, LVH, LV dysfunction, and atherosclerosis, it
could be argued that RAS blockade therapy may potentially
be beneficial in patients with AS. However, ACEIs and
ARBs are perceived as being relatively contraindicated due
to general concerns regarding the use of vasodilators in AS
(8). Therefore, we sought to investigate the impact of RAS
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tality and cardiovascular (CV) events in patients with AS in
a large population-based cohort.
Methods
Study design. This was a retrospective, population-based
longitudinal cohort study. Data on all patients with a new
diagnosis of AS were ascertained from a clinical echocar-
diogram database maintained by the Cardiology Department
at Ninewells Hospital, Tayside, Scotland. These echocardio-
graphic data were then linked to the MEMO (Medicines
Monitoring Unit) community-dispensed prescriptions da-
tabase maintained by the University of Dundee, which
contains detailed prescribing on all residents in Tayside
(population 400,000) since 1993. Other clinical datasets
including laboratory test results, hospital admissions (Scot-
tish Morbidity Record), mortality data (General Registry
Office), and data from primary care were also linked through
a patient-unique identifier called the community health
index number. The use of the community health index
number in Tayside to document all health-related activity
over the past 20 years facilitates high accuracy record linkage
at the level of the individual. Access to the anonymized and
validated clinical datasets was administered by the Health
Informatics Centre at the University of Dundee using
established protocols approved by the Research Ethics
Committee in Tayside.
Study population. All patients receiving a diagnosis of AS
between September 1993 and July 2008 were identified
from the echocardiogram database. The diagnosis and
severity of AS were ascertained by British Society of
Echocardiography accredited echocardiographers at the
time of scan based on peak aortic velocity, mean aortic
gradient, and orifice area information according to standard
guidelines (9). Patients were entered in the study from the
date of the first echocardiogram indicating AS, whereas
those with a history of malignancy were excluded. Data on
comorbidities and clinical variables were obtained from the
merged clinical datasets around the time of index echocar-
diographic diagnosis of AS. The in-treatment blood pres-
sure (BP) was defined as the average of all available BP
readings over the follow-up period. Patients with AS who
had at least 2 prescriptions dispensed for either an ACEI or
an ARB constituted the ACEI/ARB group (cases), whereas
all other patients who were never prescribed an ACEI or an
ARB were analyzed as the control (no ACEI/ARB) group.
Patients in whom cancer developed during the follow-up
were excluded from the survival analysis for mortality outcome.
Outcomes. Outcome measures included all-cause mortal-
ity and CV events (CV death or hospitalizations). CV
hospitalizations were ascertained from Scottish Morbidity
Record database coded by primary ICD-9 (codes 410, 411,
413, 428, 430 through 438, and 440 through 443) and
ICD-10 (codes I20 through I22, I50, I60 through I64, and
I70 through I73) for myocardial infarction, angina, heartfailure, cerebrovascular accident,
atherosclerosis, aortic aneurysm,
and peripheral vascular disease.
CV deaths were ascertained from
the General Registry Office da-
tabase with the main cause of
death being diseases of circula-
tory system (ICD-9 codes of 390
to 459 and ICD-10 codes of I00
through I99). Outcome data
were assessed in September
2008, and patient follow-up was
censored when they either had
AVR or outcome event or if they
were lost to follow-up.
Statistical analyses. Character-
istics of patients with or without
ACEI/ARB therapy were com-
pared by the chi-square test for
categorical variables and by the t
test or Mann-Whitney U test for continuous variables as
appropriate. For the longitudinal analysis, Kaplan-Meier
survival curves were generated, and the differences between
survival distributions were assessed using the log-rank test.
The effects of known prognostic clinical and echocardio-
graphic variables on the outcome were examined together
with the significant differences found at baseline using the
Cox proportional hazards regression analysis. The following
covariates were included: severity of stenosis, age, sex, social
deprivation, LV systolic function, interventricular septal
thickness, diabetes, renal disease, CV history, and concur-
rent use of other cardiovascular drugs including statins. To
minimize confounding influences, we performed several
sensitivity analyses. First, we determined a propensity score
(a conditional probability of exposure to a treatment given
observed covariates including concurrent CV drugs such as
statins) using a logistic regression model. We subsequently
used the score to perform a subgroup analysis in which
cohorts of ACEI/ARB exposed and unexposed subjects
were matched for propensity score. Second, the association
between ACEI/ARB and cardiovascular events was assessed
by using a Cox regression model with a time-dependent
variable for ACEI/ARB exposure. Third, we repeated our
analyses in a subgroup of patients for whom the BP data
were available. All statistical analyses were performed using
SAS version 9.1 (SAS Institute, Cary, North Carolina), and
a p value 0.05 (2-sided) was considered significant.
Results
Patient characteristics. A total of 2,117 patients with AS
(age 73  12 years, 46% men) were identified. The stenosis
was nonsevere (mild to moderate) in 1,585 (75%) patients,
whereas 532 (25%) had severe AS. A total of 699 patients
(33%) received ACEIs or ARBs (ACEIs, n  611; ARBs,
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severe AS (37% vs. 20%).
Comparison of patients with and without ACEIs/
ARBs. Table 1 shows the comparison of study patients
with and without ACEI/ARB therapy. Patients taking
ACEIs/ARBs were younger (mean age 73 years vs. 74 years;
p  0.01) and had significantly higher prevalence of
diabetes (28% vs. 12%, p  0.0001), previous CV event
(29% vs. 19%, p  0.0001), LV systolic dysfunction (14%
vs. 11%, p 0.04), and concurrent prescription of other CV
drugs.
Effect of ACEIs/ARBs on outcomes. The mean follow-up
was 4.2 years, and 78% of the total study population had a
minimum follow-up of 2 years (76% in the ACEI/ARB
group and 83% in no ACEI/ARB group). There was a total
of 1,087 all-cause deaths, 284 in the ACEI/ARB group and
803 in the no ACEI/ARB group. Similarly, there were
1,018 CV events (CV death or hospitalization), 266 in the
ACEI/ARB group and 752 in the no ACEI/ARB group
(Table 2). Figure 1 shows the effect of ACEI/ARB therapy
on survival in patients with AS using Kaplan-Meier analysis
and log-rank statistic. Unadjusted and adjusted hazard
ratios (HRs) for all-cause mortality and CV events are
shown in Table 3. ACEI/ARB therapy was associated with
significantly lower all-cause mortality (HR: 0.76, p 
Clinical Characteristics of AS PatientsW th or Withou ACEI/ARB TherapyTable 1 Clinical Characteristics of AS PatientsWith or Without ACEI/ARB Therapy
Variable
ACEI/ARB
(n  699)
No ACEI/ARB
(n  1,418) p Value
Age, yrs 73 10 74 13 0.01
Male 49 45 NS
Serum creatinine, mmol/l 115 70 103 46 NS
Severity of AV stenosis
Mild to moderate 84 70 0.0001
Severe 16 30 0.0001
Peak AV gradient, mm Hg 44 23 50 29 0.01
Peak AV velocity, m/s 3.3 0.9 3.5 0.7 0.01
Mean AV gradient, mm Hg 30 17 38 19 0.01
AV area, cm2 1.0 0.4 0.9 0.4 0.01
LV systolic dysfunction 14 11 0.04
Comorbidities
Diabetes 28 12 0.0001
Renal failure 3.0 2.3 NS
Previous CV event 29 19 0.0001
Medications
Aspirin 70 40 0.0001
Anticoagulant 25 13 0.0001
Spironolactone 13 12 NS
Beta-blocker 46 22 0.0001
Calcium channel blocker 55 24 0.0001
Digoxin 25 14 0.0001
Nitrates 44 24 0.0001
Statins 60 18 0.0001
Other lipid-lowering drugs 5.3 1.4 0.0001
Values are mean  SD or %.i
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; AS 
ortic stenosis; AV  aortic valve; CV  cardiovascular; LV  left ventricular.0.0001) and CV events (HR: 0.77, p  0.0001). We also
stratified outcome data based on the echocardiographer-
defined severity of AS. ACEI/ARB therapy was associated
with a 22% (p  0.01) lower risk of CV events in patients
with nonsevere AS (mild to moderate stenosis) and a 36%
(p  0.04) lower risk of CV events in those with severe AS
(Table 4).
Propensity score-matched cohort analysis. To minimize
the potential bias inherent with discharge prescription of
ACEIs or ARBs, we also performed a propensity score–
matched cohort analysis. This particular cohort consisted of
532 individuals with 266 patients in each group (ACEI/
ARB vs. no ACEI/ARB). The unadjusted HR for CV
events in this analysis was 0.60 (95% confidence interval
[CI]: 0.46 to 0.78), whereas the adjusted HR was 0.71 (95%
CI: 0.53 to 0.96). For all-cause mortality, the unadjusted
and adjusted HRs were 0.53 (95% CI: 0.40 to 0.69) and
0.67 (95% CI: 0.50 to 0.93), respectively.
Time-dependent analysis. The time-dependent analysis
further supported these findings with an adjusted HR of
0.45 (95% CI: 0.20 to 0.97) for CV events.
In-treatment BP and ACEIs/ARBs. Data on the in-
treatment BP (defined as average of all available BP record-
ings over the follow-up period) were only available for 330
patients (187 in the ACEI/ARB group and 143 in the no
ACEI/ARB group). However, both average systolic BP
(138  17 mm Hg vs. 137  17 mm Hg, p  0.51) and
iastolic BP (72  9 mm Hg vs. 72  10 mm Hg, p 
.62) did not differ significantly between the 2 groups in this
ohort.
iscussion
his study had 2 main findings. First, ACEI/ARB therapy
as associated with lower all-cause mortality and CV event
ate during the follow-up in patients with AS. This re-
ained so after correction for multiple confounding influ-
nces. Second, this observed lower risk of all-cause mortality
nd CV events was evident in both patients with nonsevere
mild to moderate) AS as well as in those with severe AS.
o the best of our knowledge, this is the largest retrospec-
ive observational study investigating the impact of RAS
lockade therapy with ACEIs/ARBs on outcome in AS
atients.
eyond the valve: aortic valvular “heart” disease. There
Total Number of EventsTable 2 Total Number of Events
Outcome
All Patients
(N  2,117)
ACEI/ARB
(n  699)
No ACEI/ARB
(n  1,418)
CV hospitalization 587 (28) 120 (17) 467 (33)
CV death 431 (20) 146 (21) 285 (20)
AVR 155 (7) 36 (5) 119 (8)
All-cause mortality 1,087 (51) 284 (41) 803 (57)
Values are n (%).
AVR  aortic valve replacement; other abbreviations as in Table 1.s a growing appreciation that AS incorporates a disease
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to an aortic valvular “heart” disease. In AS, the increasing
afterload forces the myocardium to remodel and become
hypertrophied in an effort to maintain adequate cardiac
output and systolic function (10). The hypertrophied myo-
cardium is not all myofibrillar hypertrophy because there is
Figure 1 Kaplan-Meier Survival Curves
Kaplan-Meier survival curves for adjusted cumulative survival in the study populati
angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)deposition of collagen and fibronectin as well. Patients withAS also commonly have myocardial ischemia. Apart from
coexistent coronary artery disease, the valvular obstruction
alone results in myocardial ischemia with diminished coro-
nary flow reserve and reduced transmural perfusion gradi-
ent, even in the presence of angiographically normal coro-
naries (11–13). The myocardial fibrosis is perpetuated
tified by the use of
y. (A) All-cause mortality. (B) Cardiovascular (CV) events.on stra
therapfurther by subendocardial ischemia and eventually leads to
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trophied myocardium with fibrosis, jeopardized by is-
chemia, may also lead to potentially fatal ventricular ar-
rhythmias. There is evidence to show that these maladaptive
LV changes may actually persist with consequent increased
operative mortality and adverse long-term outcome despite
AVR (16,17).
The RAS is known to modulate adverse LV remodeling
and myocardial fibrosis caused by the increased afterload of
AS (3). Hence, drugs that block the RAS may be beneficial
in patients with AS, although this class of drug had been
perceived to be contraindicated in patients with AS (8). The
notion that ACEIs or ARBs may cause severe hypotension
as a result of vasodilation in the face of fixed LV outflow
obstruction describes a rare event and does not appear to be
very well substantiated by clinical evidence (8,18). Indeed,
prospective studies have shown that ACEIs are well toler-
ated, even in severe AS. O’Brien et al. (19) demonstrated
that the use of ACEIs is safe and well tolerated in patients
with mild to moderate AS with preserved LV function.
Chockalingam et al. (20) studied the use of ACEIs in
symptomatic patients with severe AS who were not candi-
dates for surgery. They also found that ACEIs were well
tolerated even in severe AS.
What are the possible explanations for the beneficial
effects of ACEIs and ARBs in patients with AS? AS
patients who have coexistent coronary artery disease and
myocardial ischemia could benefit from the cardioprotective
effects of ACEI therapy (21). The atherosclerotic plaque–
stabilizing effects and consequent reduction in CV events
conferred by ACEIs could possibly explain the early diver-
gence of survival curves observed in our study (22). Simi-
larly, antiarrhythmic effects of the higher potassium levels
seen in conjunction with ACEI therapy may be relevant
here because AS in many ways is an arrhythmic substrate
(23). It should be noted that calcific AS and atherosclerosis
have similar predisposing risk factors and share pathophys-
iological features (24,25). Moreover, it is increasingly rec-
ognized that AS is not caused by ”wear and tear” but results
Adjusted and Unadjusted HRs forll-Cause Mortality and CV EventsTable 3 Adjusted and Unadju ted HRs forAll-Cause Mortality and CV Events
Outcome
Unadjusted HR
(95% CI) p Value
Adjusted HR
(95% CI) p Value
All-cause mortality 0.58 (0.50–0.66) 0.0001 0.76 (0.62–0.92) 0.0001
CV events 0.64 (0.56–0.74) 0.0001 0.77 (0.65–0.92) 0.0001
CI  confidence interval; HR  hazard ratio; other abbreviations as in Tables 1 and 2.
Adjusted HRs for All-Cause Mortality and CV EvTable 4 Adjusted HRs for All-Cause Mortalit
Severity of AS n (%)
CV Events
HR (95% C
Mild to moderate 1,585 (75) 0.78 (0.64–0.
Severe 532 (25) 0.64 (0.42–0.Abbreviations as in Tables 1, 2, and 3.from an active disease process (26). ACEI therapy has also
been reported to be associated with reduced AV calcification
in AS (27). Thus, it is also possible that ACEIs may have
slowed the progression of AS. In our study, those on
ACEI/ARB therapy had a lower rate of AVR. However, it
is important to note that in another retrospective echocar-
diographic study of 211 patients with native AS, ACEIs did
not seem to have any significant impact on Doppler param-
eters of hemodynamic progression (28). Another important
consideration is the BP-lowering effect of ACEI/ARB
therapy. However, in this study, we did not observe any
significant difference in the in-treatment BP between the 2
groups. Finally, as discussed earlier, the RAS is implicated
in the adverse LV remodeling process often seen in AS,
which is associated with a poor prognosis in these patients.
Therefore, modulation of LV response to pressure overload
by RAS blockade with ACEI/ARB therapy may also have
contributed to the improved outcome (3,17,18,29–32).
Obviously, any indication that the observed outcomes are
due to the effects of ACEI/ARB therapy at the valvular,
ventricular, or systemic level is purely speculative and cannot
be inferred directly from this retrospective observational
study. Although the inhibition of the RAS may result in an
improved outcome by preventing CV events, modulating
LV response to pressure overload and possibly by delaying
progression of the valvular disease in AS, the LV outflow
obstruction due to a stenosed orifice remains a mechanical
issue with valve replacement being the only definitive
therapy to improve long-term survival. This, at least in part,
explains why there was some apparent convergence of the
Kaplan-Meier survival curves at the end in our study.
Study strengths and limitations. We recognize the limi-
tations of our study inherent with any retrospective, non-
randomized, observational data. However, the current study
reflects the true population and a real-world scenario and
adds to previous studies by selecting a large number of
patients with a varying degree of AS. In common with all
observational studies, it was impossible in our study to
account for all confounding influences that may have biased
the observed differences between the groups considered. We
do not have comprehensive data on mean dose of ACEI or
ARB therapy, making the intensity of exposure difficult to
measure. However, only a randomized, controlled trial can
remove the bias and reliably measure exposure to treatment.
We have addressed issues of potential treatment bias and
baseline imbalance of covariates between the groups by
performing 3 different sensitivity analyses. First, by using a
Stratified by Severity of ASCV Events Stratified by Severity of AS
p Value
All-Cause Mortality
HR (95% CI) p Value
0.01 0.76 (0.61–0.95) 0.01
0.04 0.75 (0.49–1.15) NSentsy and
I)
94)
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second, by performing a propensity score–matched analysis,
and third, by time-dependent variable analysis. The propen-
sity score–matched analysis has been shown to eliminate as
much as 90% of treatment bias in observational studies (33).
It should also be noted that those in the ACEI/ARB group
had a higher incidence of significant comorbidities includ-
ing diabetes, LV dysfunction, and previous CV events at
baseline, which may explain why these patients were origi-
nally prescribed these drugs. Additionally, more patients in
the ACEI/ARB group were prescribed digoxin and antico-
agulants, suggesting underlying atrial fibrillation, which is
another poor prognostic factor in AS (34). Arguably, these
differences at baseline, if anything, would suggest that those
in the ACEI/ARB group were actually at a much higher
risk compared with patients who did not receive such
therapy. Despite this higher risk at baseline, we found that
patients with AS who received ACEI/ARB therapy had a
significantly better outcome.
Conclusions
This is the largest retrospective analysis of the use of RAS
blockade therapy with ACEIs or ARBs in AS. Despite
concerns over safety of ACEIs and ARBs, we have found
evidence to suggest that therapy with ACEIs or ARBs is
associated with an improved survival and a reduction in CV
events in patients with varying degrees of AS. Prospective,
randomized, controlled trials are warranted to confirm these
findings.
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